Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
DOI10.1007/S00362-016-0790-7zbMATH Open1398.62351OpenAlexW2467367917WikidataQ54987395 ScholiaQ54987395MaRDI QIDQ725696FDOQ725696
Authors: Graham M. Wheeler 
Publication date: 2 August 2018
Published in: Statistical Papers (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1007/s00362-016-0790-7
Recommendations
- Coherence principles in dose-finding studies
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Number of patients per cohort and sample size considerations using dose escalation with overdose control
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50) Sequential statistical design (62L05)
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Coherence principles in dose-finding studies
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Design and Analysis of Phase I Clinical Trials
- Basic concepts of multiple tests -- a survey
- Bayesian and robust Bayesian analysis under a general class of balanced loss functions
- A Bayesian approach for the estimation of probability distributions under finite sample space
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Incorporating individual and collective ethics into phase I cancer trial designs
- Unifying CRM and EWOC designs for phase I cancer clinical trials
Cited In (5)
- A continual reassessment method without undue risk of toxicity
- Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Number of patients per cohort and sample size considerations using dose escalation with overdose control
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
Uses Software
This page was built for publication: Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q725696)
